Congratulations to our portfolio company BillionToOne on serving more than 500K patients thus far, growing from $0M to $125M of annualized revenue over approximately the past 4 years, and raising an oversubscribed $130M Series D round at a greater than $1B valuation! We're fortunate to have partnered with BillionToOne since its Series A round in 2019, and we're excited about BillionToOne's quest to help millions of patients with its best-in-class prenatal tests and liquid biopsy products in the future!
Today we announced the successful completion of a Series D funding round, raising $130 million and bringing our total valuation to over $1B. The round was led by Premji Invest and Neuberger Berman, with participation from our existing investors. The funds will be allocated to further scale our prenatal screening and oncology diagnostics businesses, expanding the reach of our innovative tests powered by our proprietary Quantitative Counting Templates (QCTs) technology. Over 500,000 patients have benefited from our cutting-edge tests to date. We appreciate the support of our investors and the dedication of our team as we work towards our mission to make molecular diagnostics more powerful, efficient, and accessible for all. Read our press release here ➡ https://lnkd.in/gj5fF9hH Claire Rychlewski from Axios wrote about the news here ➡ https://lnkd.in/gd-FeKhh #oncology #prenatalhealth #moleculardiagnostics #BillionToOne #UNITY #Northstar #Axios